2nd Annual Drug Repurposing and Repositioning

The pipeline for the drug industry is filled with drugs that fail to emerge as products despite the millions spent on them.  Repurposing or repositioning existing drugs can add value by accelerating drug development while reducing risk and lowering investment costs.  The idea is to take advantage of existing information and choose known compounds for further development.  Drug repurposing and repositioning can be accomplished by adding new indications, modifying compounds and changing and improving formulation and/or delivery.

The conference will focus on the following topics:

• Identify suitable compounds and opportunities for repurposing
• Secondary patent opportunities
• Business of repurposing and repositioning
• Technology facilitating repurposing

Distinguished speakers include the following:

• Louis Tartaglia, Senior Vice President and General Manager, Gene Logic
• Chizuko Koseki, Vice President, Drug Reprofiling Platform Unit, Sosei Co. Ltd.
• Herwig von Morze, International Patent Consultant, formerly Heller Ehrman LLP
• Glynn Wilson, Chairman and President, Auriga Laboratories, Inc.

Pre-Conference Workshop on 505(b)(2) led by:

• Karin Kook, Managing Director, Salamandra LLC
• James Czaban, Shareholder, Heller Ehrman LLP

Hear what some of our previous attendees had to say:

“Innovative, pragmatic biotech companies are increasingly creating new drugs built from repurposed known agents and CBI has provided a leading venue for showcasing their novel discoveries”. 
--Daniel Grau, Vice President, Corporate Development and Strategy, CombinatoRx

For more information or to register, please contact the Center for Business Intelligence toll free by phone at 1-800-817-8601 or via e-mail at cbireg@cbinet.com.